# Clinical Trials Data ERBB2 - Document 10

# Prognostic Relevance of Biological Subtype in Breast Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT02063906

"eligibilityCriteria": "Inclusion Criteria:\n\n\* patients who received curative surgery\n\* stage I-III breast cancer\n\* between January 2004 and September 2008\n\* had available immunohistochemistry profiles.\n\nexclusion Criteria:\n\n\* age \\<18 years old\n\* microinvasive carcinoma of breast",  
 "healthyVolunteers": false,  
 "sex": "FEMALE",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Patients who received curative surgery for stage I-III breast cancer between January 2004 and September 2008 and had available immunohistochemistry profiles.",

Question:  
Based on the following clinical trial information, would a patient with a ERBB2 gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria for the clinical trial, the presence of an ERBB2 gene mutation is not mentioned as either an inclusion or exclusion factor. Therefore, if a patient with an ERBB2 gene mutation meets the other eligibility criteria—such as having received curative surgery for stage I-III breast cancer between January 2004 and September 2008, being older than 18 years, and having available immunohistochemistry profiles—they would likely be eligible for this clinical trial. However, it's always important to consult the study investigators or trial coordinators for confirmation and any additional unexplored criteria.